Merck KGaA raises 2026 EBITDA target and full-year sales outlook

The German family-controlled life-sciences and chemicals group cited stronger demand for drug manufacturing supplies and semiconductor materials, robust operating performance, and easing foreign-exchange pressure.

19d ago

Summary

Merck KGaA raised guidance after better-than-expected quarterly results, increasing its 2026 adjusted EBITDA target, excluding special items, to EUR5.9 billion-EUR6.3 billion from EUR5.7 billion-EUR6.1 billion. It also lifted its full-year 2024 net sales outlook for a second straight quarter to EUR21 billion-EUR21.8 billion, with 1%-3% organic growth, from EUR20.4 billion-EUR21.4 billion and a prior forecast of flat to 3% organic growth; the new EBITDA range compares with EUR6.1 billion reported for last year.

Terms & Concepts

Adjusted EBITDA: Earnings before interest, taxes, depreciation and amortisation, excluding special items, used as a measure of operating profitability.
Organic growth: Revenue growth measured excluding effects such as acquisitions, divestments, and currency movements.
Foreign-exchange headwinds: Adverse currency movements that reduce reported sales or earnings when results are translated into the reporting currency.